• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

INmune Bio Inc. - Common stock (NQ:INMB)

1.870 +0.040 (+2.19%)
Streaming Delayed Price Updated: 1:02 PM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about INmune Bio Inc. - Common stock

< Previous 1 2 3 Next >
INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025
Today 7:00 EDT
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal
September 29, 2025
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult
September 15, 2025
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment
August 04, 2025
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th
July 31, 2025
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer’s Association International Conference
July 29, 2025
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference
July 24, 2025
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
June 30, 2025
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease
June 30, 2025
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
June 27, 2025
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th
June 26, 2025
From INmune Bio, Inc.
Via GlobeNewswire
XPro™ Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer’s Disease: Supported by Department of Defense
June 10, 2025
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference
May 14, 2025
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th
May 05, 2025
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology
April 16, 2025
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness
April 14, 2025
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study
April 01, 2025
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025
March 24, 2025
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer
February 12, 2025
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
February 10, 2025
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans
January 28, 2025
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt
December 10, 2024
From INmune Bio, Inc.
Via GlobeNewswire
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower
December 04, 2024
From OmniScience
Via Business Wire
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower
December 04, 2024
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
November 13, 2024
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
October 28, 2024
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
October 24, 2024
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024
October 24, 2024
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit
October 11, 2024
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease
September 30, 2024
From INmune Bio, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Recent Quotes
View More
Symbol Price Change (%)
GOOG  246.80
+2.16 (0.88%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap